SignatureFD
TLX icon

SignatureFD’s Telix Pharmaceuticals TLX Stock Holding History

SignatureFD’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.62K Hold
148
– – ﹤0.01% 3229
2026
Q2 		$1.71K Buy
+148
New +$1.51K ﹤0.01% 3164

Other funds holding TLX

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Aubrey Capital Management
Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return
WoodTrust Financial
WoodTrust Financial Wisconsin Rapids, Wisconsin $825M AUM 20.13% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EverSource Wealth Advisors
EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return
Wilmington Savings Fund Society
Wilmington Savings Fund Society Wilmington, Delaware $4.39B AUM 17.99% 1-Year Est. Return
Aspect Partners
Aspect Partners Fairfax, Virginia $264M AUM 15.76% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

SignatureFD's TLX Position: Q3 2026 in Review

SignatureFD held its Telix Pharmaceuticals (TLX) position steady in Q3 2026 at 148 shares worth $1.62K. The position accounts for ﹤0.01% of the portfolio, ranked #3229.

SignatureFD first reported a position in TLX in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.71K in Q2 2026. 20 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

  • SignatureFD held 148 shares of Telix Pharmaceuticals worth $1.62K as of Q3 2026.
  • SignatureFD left its Telix Pharmaceuticals share count unchanged in Q3 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #3229 holding.
  • SignatureFD first reported a position in Telix Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • SignatureFD's Telix Pharmaceuticals position peaked at $1.71K in Q2 2026.
  • 20 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.